Last €0.33 EUR
Change Today +0.007 / 2.19%
Volume 0.0
As of 2:20 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

bionomics ltd (B1N) Snapshot

Open
€0.33
Previous Close
€0.32
Day High
€0.34
Day Low
€0.33
52 Week High
03/10/14 - €0.48
52 Week Low
05/20/14 - €0.22
Market Cap
136.2M
Average Volume 10 Days
700.0
EPS TTM
--
Shares Outstanding
417.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIONOMICS LTD (B1N)

Related News

No related news articles were found.

bionomics ltd (B1N) Related Businessweek News

No Related Businessweek News Found

bionomics ltd (B1N) Details

Bionomics Limited discovers and develops biopharmaceuticals for the treatment of cancer and disorders of the central nervous system in Australia, France, and the United States. The company develops small molecule and antibody therapeutics in the areas of cancer, anxiety, depression, and Alzheimer's disease. Its oncology approach includes cancer stem cell therapeutics, as well as vascular disruption in solid tumors. The company’s product pipeline includes BNC105, a novel compound in Phase II clinical trials to disrupt the blood vessels that nourish tumours in cancer treatment; and BNC101, a monoclonal antibody that targets cancer stem cells. It is also developing BNC210/IW-2143 for the treatment of anxiety disorders; BNC375, a small molecule therapeutic for the treatment of cognitive impairment in Alzheimers's disease; and Kv1.3 inhibitors for the treatment of inflammatory disorders. In addition, the company, through its subsidiary, Neurofit SAS, offers contract research services. It has collaboration, research, and licensing agreements with Ironwood Pharmaceuticals, Inc.; Merck & Co.; Cancer Therapeutics Cooperative Research Center; Genmab A/S; Laboratory Corporation of America; Athena Diagnostics, Inc.; and Genetic Technologies Limited. The company was founded in 1998 and is based in Thebarton, Australia.

Founded in 1998

bionomics ltd (B1N) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$407.6K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$160.8K
Chief Medical Officer
Total Annual Compensation: A$378.9K
Compensation as of Fiscal Year 2014.

bionomics ltd (B1N) Key Developments

Bionomics Begins Phase 1b Study with Anxiety Drug BNC210

Bionomics Ltd. has initiated a Phase 1b clinical trial in healthy volunteers of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression. The trial will be conducted by Biotrial International at its facility in Rennes, France and will investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BNC210. This is a randomised, double-blind, placebo-controlled trial and will treat over 50 healthy male volunteers in sequential multiple ascending doses. Four groups of subjects will be enrolled to receive one of four doses of BNC210 or placebo, twice a day for eight days. Target engagement by BNC210 will be investigated through the use of a nicotine challenge where the subjects response to nicotine will be monitored by a brain EEG. All subjects on the study will undergo a standard battery of pharmacodynamic assessments. The primary endpoint of the trial will be the safety and tolerability of BNC210 following multiple administrations with secondary endpoints investigating the pharmacokinetic and pharmacodynamic profile of BNC210 and its effect on cognitive functions and the response to nicotine. In addition a Phase 2a study for BNC210 in human patients suffering anxiety is planned with the trial anticipated to commence during first quarter of 2015 in the UK. These trials mark vital steps in the development of BNC210 and will position it for partnering opportunities.

Bionomics Ltd. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Bionomics Ltd. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Bionomics to Progress BNC210 in Clinical Trials

Bionomics Limited announced that it will accelerate and progress BNC210 into further human clinical trials expected to commence before the end of the year 2014. In January 2012 Bionomics entered into a collaboration, research & licensing agreement with Ironwood Pharmaceuticals, Inc, for the worldwide development and commercialization of BNC210. Bionomics and Ironwood have now mutually agreed to terminate this arrangement. Ironwood will retain a royalty interest in BNC210 whilst Bionomics has re-acquired exclusive worldwide rights to develop, commercialize and partner BNC210. Bionomics intends to progress the clinical development of BNC210 to significantly enhance its value prior to further partnering, building on the substantial progress already made through the Ironwood collaboration. Bionomics has received approval to commence a phase Ib clinical trial in France to be conducted by Biotrial International Limited. The trial will examine target engagement by BNC210, based on its mechanism of action. Details of the trial are provided in the clinical appendix following this announcement. It is anticipated that this trial will allow further refinement of BNC210 dose levels to be evaluated in Phase II. In addition Bionomics will shortly make a submission to commence a phase II trial in patients with anxiety. Pending approval, this trial is anticipated to commence in first quarter of 2015. Clinical Trial Appendix: Bionomics is conducting a single-centre Phase Ib multiple ascending dose clinical trial (BNC210.005) with BNC210 to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male volunteers. Primary Endpoint: Safety and tolerability of multiple ascending oral doses of BNC210 in healthy adult male subjects. Secondary Endpoints: Preliminary pharmacokinetic profile of multiple ascending doses of BNC210. Pharmacodynamic profile of multiple ascending oral doses of BNC210 on cognitive functions. Pharmacodynamic profile of multiple administrations of the higher dose on nicotine shift. Four groups of subjects will be enrolled to receive one of each of four doses of BNC210 or placebo, twice a day for eight days. All subjects on the study will undergo a standard battery of pharmacodynamic assessments measuring cognitive parameters: Choice Reaction Time, Digit Vigilance, Rapid Visual Information Processing, Learning Memory Test, Numeric Working Memory test and Spatial Working Memory test, or subjective feelings produced by the drug: Bond and Lader Visual Analogue Scale, and Addiction Research Centre Inventory (ARCI) 49.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B1N:GR €0.33 EUR +0.007

B1N Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for B1N.
View Industry Companies
 

Industry Analysis

B1N

Industry Average

Valuation B1N Industry Range
Price/Earnings 45.2x
Price/Sales 6.6x
Price/Book 4.9x
Price/Cash Flow 45.3x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit www.bionomics.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.